Related Experiment Videos
Multiple endocrine neoplasia type 2. Clinical features and screening
F Raue1, K Frank-Raue, A Grauer
1Department of Internal Medicine I, University of Heidelberg, Germany.
Endocrinology and Metabolism Clinics of North America
|March 1, 1994
Summary
Prospective screening programs enable early diagnosis of Multiple Endocrine Neoplasia type 2 (MEN 2) by identifying gene mutations and detecting early signs of medullary thyroid carcinoma and pheochromocytoma.
Area of Science:
- Endocrinology
- Genetics
- Oncology
Background:
- Multiple Endocrine Neoplasia type 2 (MEN 2) is a genetic disorder.
- It is characterized by medullary thyroid carcinoma, pheochromocytoma, and parathyroid disease.
- Traditional presentation often involves advanced disease stages.
Purpose of the Study:
- To highlight the impact of prospective screening on MEN 2 clinical features.
- To emphasize the early diagnosis of MEN 2 manifestations.
- To discuss the role of genetic testing and biochemical screening.
Main Methods:
- Characterization of specific gene mutations for carrier status identification.
- Prospective screening for early medullary thyroid carcinoma using calcitonin testing.
- Routine screening for pheochromocytoma using various diagnostic techniques.
Main Results:
- Prospective screening has significantly altered the clinical presentation of MEN 2.
- All manifestations of MEN 2 syndrome are now diagnosable at an early stage.
- Early detection of medullary thyroid carcinoma and pheochromocytoma is routinely achievable.
Conclusions:
- Early diagnosis of MEN 2 is facilitated by prospective screening programs.
- Genetic identification of carriers allows for timely intervention.
- Screening protocols enable the detection of MEN 2 manifestations before significant clinical progression.